Contratos Río Hortega 2021. Aitana Balaguer.
Datos básicos
- Protocolo:
- CM21/00244
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- 2022
- Año de finalización:
- 2024
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Chihara D; (...); Yakoub-Agha I
Letter. 10.3324/haematol.2022.281754. 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini, Enrico; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02027-y. 2023
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Berning, Philipp; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2022-164637. 2022
Allogeneic hematopoietic stem cell transplantation achieves long-term survival in Natural killer/T-cell lymphoma in the era of Asparaginase-based Chemotherapy
Berning, P.; (...); Glass, B.
Meeting Abstract. 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Berning, Philipp; (...); Glass, Bertram
Article. 10.1038/s41375-023-01924-x. 2023
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-01940-6. 2023
ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY
Bug, Gesine; (...); Mohty, Mohamad
Meeting Abstract. 2023
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M; (...); Barba P
Article. 10.3324/haematol.2022.280805. 2023
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Bastos-Oreiro, Mariana; (...); Garcia-Sancho, Alejandro Martin
Article. 10.3389/fimmu.2022.855730. 2022
Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC
Pena, Marta; (...); Balari, Anna Maria Sureda
Meeting Abstract. 10.1182/blood-2023-181815. 2023
CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model
Ferrer Lores, Blanca; (...); Jose Terol, Maria
Meeting Abstract. 10.1182/blood-2023-185088. 2023
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice
Chiusolo, Patrizia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182831. 2023
Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide
Piemontese, Simona; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182923. 2023
Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT.
Ruggeri, Annalisa; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.07.006. 2022
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe, Mizuki; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2023010598. 2024
CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1111/bjh.19130. 2023
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Correction. 10.1038/s41409-023-01967-9. 2023
Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1016/j.cmi.2023.05.010. 2023
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1038/s41409-023-02075-4. 2023
EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.
Canto, Pedro Asensi; (...); Segui, Ines Gomez
Article. 10.1016/j.jtct.2023.07.001. 2023
Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Espanol De Trasplante y Terapia Celular (GETH-TC) Study
Fabbri, Nicole; (...); Mussetti, Alberto
Meeting Abstract. 10.1182/blood-2023-185721. 2023
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/bloodadvances.2023012133. 2024
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000790. 2022
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2023
Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.08.018. 2022
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1111/bjh.18765. 2023
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Torrent, Anna; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-186388. 2023
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.
Oreiro MB; (...); García-Sancho AM
Article. 10.1016/j.jtct.2023.08.026. 2023
Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
Bastos-Oreiro, Mariana; (...); Martin Garcia-Sancho, Alejandro
Meeting Abstract. 10.1182/blood-2022-166329. 2022
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
Im, Annie; (...); Pavletic, Steven Z.
Meeting Abstract. 10.1182/blood-2022-169605. 2022
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02012-5. 2023
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-156231. 2022
Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-186293. 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES
Papanicolaou, Genovefa; (...); Hirji, Ishan
Meeting Abstract. 2023
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1186/s13045-023-01450-4. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)
Nagler, Arnon; (...); Mohty, Mohamad
Correction. 10.1186/s13045-023-01501-w. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT
Heinicke, Thomas; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-174233. 2023
Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.
Perez, Ariadna; (...); Pinana, Jose Luis
Article. 10.1007/s15010-024-02213-0. 2024
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socie, Gerard; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02127-9. 2024
OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 2023
Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
Baron F; (...); Mohty M
Article. 10.1038/s41409-023-02000-9. 2023
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii, Hanadi; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2022007941. 2022
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Meeting Abstract. 2023
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
Wieczorek, Michele; (...); Mohty, Mohamad
Letter. 10.1002/ajh.26782. 2022
Post-transplant cyclophosphamide separates graft-versus host disease (GVHD) and graft versus leukemia (gvl) effects after HLA- matched stem-cell transplantation (sct) for AML
Shimoni, A.; (...); Mohty, M.
Meeting Abstract. 2022
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel, Sebastian; (...); Mohty, Mohamad
Article. 10.1002/cncr.35004. 2023
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with all treated in CR1 with allo-HCT from matched unrelated donors. A study from ALWP of the EBMT
Giebel, S.; (...); Mohty, M.
Meeting Abstract. 2022
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro, Juan; (...); Glass, Bertram
Article. 10.1016/j.jtct.2023.11.021. 2024
Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Abou Dalle, Iman; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-187095. 2023
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-182823. 2023
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Recent advances in allogeneic transplantation for acute myeloid leukemia.
Montoro J, Balaguer-Roselló A, Sanz J
Article. 10.1097/CCO.0000000000000992. 2023
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Article. 10.1038/s41409-023-01949-x. 2023
Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
Mussetti, Alberto; (...); Sureda, Anna
Meeting Abstract. 10.1182/blood-2022-160000. 2022
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using PostTransplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-180075. 2023
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
Secondary neoplasms after umbilical cord blood transplantation. On behalf of eurocord and the european group for blood and marrow transplantation
El Ayoubi, H. Rafii; (...); Gluckman, E.
Meeting Abstract. 2022
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.
Kharfan-Dabaja, Mohamed A.; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000920. 2023
Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient.
Sahuquillo-Arce JM; (...); López-Hontangas JL
Article. 10.1099/ijsem.0.005805. 2023
T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
Swoboda, R.; (...); Mohty, M.
Meeting Abstract. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and CoOccurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party
Dalle, Abou; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-179531. 2023
Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt
Battipaglia, G.; (...); Mohty, M.
Meeting Abstract. 2022
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia, Giorgia; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2023.09.028. 2024
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Benzaquen, Ana; (...); Solano, Carlos
Article. 10.1038/s41409-023-02114-0. 2024
TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY
Hernani, Rafael; (...); Solano, Carlos
Meeting Abstract. 2023
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed, Rama; (...); Mohty, Mohamad
Article. 10.1002/cncr.34843. 2023
Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/blood.2023023697. 2024